Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
decitabine + thiotepa + busulfan + fludarabine + antithymocyte globulin
- Development stage
- Preclinical
- Lead developer
- Peking University Institute of Hematology
- Modality
- Small Molecules, Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
decitabine + thiotepa + busulfan + fludarabine + antithymocyte globulin (DTBFA) is a novel myeloablative conditioning regimen developed for patients with myelofibrosis undergoing haploidentical hematopoietic stem cell transplantation (haplo-HSCT). The regimen combines the hypomethylating agent decitabine, the alkylating agents thiotepa and busulfan, the purine analog fludarabine, and the immunosuppressant antithymocyte globulin (ATG). This combination is designed to optimize graft function, enhance myelofibrosis regression, and reduce graft failure and non-relapse mortality by tailoring the conditioning intensity based on pre-transplant spleen size.
- Other names
- decitabine + thiotepa + busulfan + fludarabine + antithymocyte globulinDTBFADTBFA regimen
02
Targets
CD3 (T-cell surface glycoprotein CD3)DNADNMT1 (DNA (cytosine-5)-methyltransferase 1)POLA1 (DNA polymerase alpha)RNR (Ribonucleotide reductase)γδ TCR (T-cell receptor)
Beyond the preview
Go deeper on decitabine + thiotepa + busulfan + fludarabine + antithymocyte globulin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on decitabine + thiotepa + busulfan + fludarabine + antithymocyte globulin.